Senseonics (NYSE:SENS) Stock Price Down 5% – Should You Sell?

Shares of Senseonics Holdings, Inc. (NYSE:SENS) dropped 5% on Wednesday . The company traded as low as $1.04 and last traded at $1.06. Approximately 4,024,237 shares traded hands during trading, a decline of 81% from the average daily volume of 21,064,957 shares. The stock had previously closed at $1.11.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SENS shares. StockNews.com initiated coverage on shares of Senseonics in a research report on Thursday, December 26th. They set a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Stock Performance

The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The stock has a market cap of $619.14 million, a price-to-earnings ratio of -8.00 and a beta of 0.64. The company’s 50-day simple moving average is $0.53 and its 200-day simple moving average is $0.43.

Senseonics (NYSE:SENS) last posted its earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. The business had revenue of $4.26 million during the quarter, compared to analyst estimates of $4.02 million. Analysts predict that Senseonics Holdings, Inc. will post -0.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Timothy T. Goodnow purchased 315,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the transaction, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Frederick T. Sullivan acquired 124,933 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the acquisition, the chief financial officer now owns 2,478,844 shares in the company, valued at $941,960.72. This represents a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently made changes to their positions in SENS. FMR LLC grew its position in Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after acquiring an additional 167,970 shares during the last quarter. Ridgecrest Wealth Partners LLC bought a new position in shares of Senseonics during the 4th quarter valued at $60,000. GSA Capital Partners LLP bought a new stake in Senseonics in the third quarter worth $117,000. Symmetry Partners LLC bought a new stake in Senseonics in the third quarter worth $164,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares during the last quarter. 12.36% of the stock is owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.